Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcine pituitary follicle-stimulating hormone (pFSH) is a protein-based gonadotropin extracted from porcine pituitary glands, currently in development by Xiamen Origin Biotech for applications in veterinary reproductive medicine. As an agonist of the follicle-stimulating hormone receptor (FSHR), it mimics the physiological role of endogenous FSH by stimulating the recruitment, growth, and maturation of ovarian follicles in female animals. This mechanism is particularly valuable in livestock management for superovulation protocols, which aim to induce the release of multiple oocytes for embryo transfer and genetic improvement programs. The product is typically administered via intramuscular injection and is designed to provide a potent and reliable source of FSH activity for synchronized breeding and assisted reproductive technologies in species such as cattle, sheep, and swine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on porcine pituitary follicle-stimulating hormone.